干扰素β而非醋酸格拉替雷治疗会加重多发性硬化症患者的头痛。

Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.

作者信息

Pöllmann W, Erasmus L-P, Feneberg W, Then Bergh F, Straube A

机构信息

Marianne-Strauss-Klinik, Berg, Germany.

出版信息

Neurology. 2002 Aug 27;59(4):636-9. doi: 10.1212/wnl.59.4.636.

DOI:10.1212/wnl.59.4.636

PMID:12196668

Abstract

Type and frequency of headaches during immunomodulatory therapy in MS were determined in 167 consecutive patients. In a prospective group of 65 patients beginning interferon beta therapy, headache frequency and duration increased in 18% of all and in 35% of patients with pre-existing headache by more than 50% during the first 6 months. In two retrospective groups, increased headache frequency was reported by 34% of 53 patients on interferon beta, but by only 6% of 49 patients during at least 6 months of glatiramer acetate therapy.

摘要

对167例连续的多发性硬化症患者在免疫调节治疗期间的头痛类型和频率进行了测定。在一个由65例开始接受干扰素β治疗的患者组成的前瞻性队列中，在最初6个月内，所有患者中有18%、已有头痛的患者中有35%头痛频率和持续时间增加超过50%。在两个回顾性队列中，53例接受干扰素β治疗的患者中有34%报告头痛频率增加，但在至少6个月接受醋酸格拉替雷治疗的49例患者中只有6%报告头痛频率增加。